Share Price | ABVC BioPharma, Inc. Stock Analysis & Recommendation

Q: How big is ABVC BioPharma, Inc.?

Market Cap: As of Jun 18, ABVC BioPharma, Inc. has a market capitalization of 34.02 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, ABVC BioPharma, Inc. reported net sales of 0.51 million and a net profit of -2.21 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1.23 million and total assets of 7.54 million.

Q: What does ABVC BioPharma, Inc. do?

Overview: ABVC BioPharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -1 Million (Quarterly Results - Mar 2025) Market Cap: USD 34.02 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.37 Return on Equity: -41.12% Price to Book: 6.29Contact Details: Registrar Address: Not available.

Q: Is ABVC BioPharma, Inc. overvalued or undervalued?

As of 14 August 2023, the valuation grade for ABVC BioPharma, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its high Price to Book Value of 4.85 and negative ratios such as EV to EBITDA at -17.19 and ROE at -41.12%. These figures suggest that the company is struggling to generate returns and is not effectively utilizing its capital.In comparison to peers, ABVC BioPharma's EV to EBITDA ratio of -21.9563 is notably worse than Tempest Therapeutics, Inc. at -0.2631 and Aptorum Group Ltd. at -2.9175, highlighting its relative underperformance in the sector. The company's recent stock performance has been impressive, with a year-to-date return of 232.20%, significantly outpacing the S&P 500's 2.44% over the same period. However, this does not mitigate the valuation concerns, as the underlying financial metrics indicate that the stock may not be justified at its current price level.

Q: Is ABVC BioPharma, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for ABVC BioPharma, Inc. has changed from bullish to mildly bullish. The current technical stance is mildly bullish, driven by daily moving averages and weekly Bollinger Bands indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The monthly RSI remains bearish, which adds to the mixed signals. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date and over the past year, with returns of 361.02% and 312.12%, respectively, compared to the S&P 500's 12.22% and 17.14%. However, the longer-term returns over 3 and 5 years show substantial underperformance relative to the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

183.74 k

Shareholding (Sep 2025)

FII

0.41%

Held by 3 FIIs

DII

96.87%

Held by 3 DIIs

Promoter

0.00%

How big is ABVC BioPharma, Inc.?

22-Jun-2025

As of Jun 18, ABVC BioPharma, Inc. has a market capitalization of 34.02 million, with net sales of 0.51 million and a net profit of -2.21 million over the last four quarters. The company reported shareholder's funds of 1.23 million and total assets of 7.54 million as of Dec 24.

View full answer

What does ABVC BioPharma, Inc. do?

22-Jun-2025

ABVC BioPharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $1 million and a market cap of $34.02 million. Key metrics include a debt-to-equity ratio of 0.37 and a return on equity of -41.12%.

View full answer

Is ABVC BioPharma, Inc. overvalued or undervalued?

25-Jun-2025

As of August 14, 2023, ABVC BioPharma, Inc. is considered overvalued with significant financial concerns, reflected in its high Price to Book Value of 4.85 and negative ratios, despite a strong year-to-date stock performance of 232.20%.

View full answer

Is ABVC BioPharma, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, ABVC BioPharma, Inc. shows a mildly bullish trend with strong year-to-date and annual performance, but mixed technical indicators suggest caution moving forward.

View full answer

Compare ABVC BioPharma, Inc. with Similar Stocks

Aptorum Group Ltd.Palisade Bio, Inc.Sonoma Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 50 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.13

Return on Equity

-36.79%

Price to Book

4.13

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Sep 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-43.26%

6 Months

-50.0%

1 Year

233.06%

2 Years

6.67%

3 Years

127.56%

4 Years

-93.65%

5 Years

-96.67%

ABVC BioPharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-3.89%

EBIT Growth (5y)

3.04%

EBIT to Interest (avg)

-6.68

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.37

Sales to Capital Employed (avg)

0.06

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.07%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.85

EV to EBIT

-14.43

EV to EBITDA

-17.19

EV to Capital Employed

3.81

EV to Sales

28.19

PEG Ratio

Dividend Yield

ROCE (Latest)

-26.39%

ROE (Latest)

-41.12%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (2.72%)

Foreign Institutions

Held by 3 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 43.48% vs -155.56% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.10",
          "val2": "-2.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.30",
          "val2": "-2.30",
          "chgp": "43.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,467.90%",
          "val2": "0.00%",
          "chgp": "-146.79%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 150.00% vs -80.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.14% vs 49.08% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.20",
          "chgp": "150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.50",
          "val2": "-6.40",
          "chgp": "29.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "1.30",
          "chgp": "-38.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.30",
          "val2": "-8.30",
          "chgp": "36.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,233.40%",
          "val2": "-44,392.40%",
          "chgp": "3,515.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.80

0.00

Operating Profit (PBDIT) excl Other Income

-1.10

-2.20

50.00%

Interest

0.00

0.10

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-1.30

-2.30

43.48%

Operating Profit Margin (Excl OI)

-1,467.90%

0.00%

-146.79%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 43.48% vs -155.56% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.50

0.20

150.00%

Operating Profit (PBDIT) excl Other Income

-4.50

-6.40

29.69%

Interest

0.80

1.30

-38.46%

Exceptional Items

0.00

Consolidate Net Profit

-5.30

-8.30

36.14%

Operating Profit Margin (Excl OI)

-9,233.40%

-44,392.40%

3,515.90%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 150.00% vs -80.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.14% vs 49.08% in Dec 2023

All Annual Results

Company CV

About ABVC BioPharma, Inc.

ABVC BioPharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

ABVC BioPharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is ABVC BioPharma, Inc.?

Watch in Real-Time

What does ABVC BioPharma, Inc. do?

Is ABVC BioPharma, Inc. overvalued or undervalued?

Is ABVC BioPharma, Inc. technically bullish or bearish?

Compare ABVC BioPharma, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About ABVC BioPharma, Inc.

Company Coordinates